Follow
Thierry André
Thierry André
Hôpital Saint Antoine
Verified email at aphp.fr
Title
Cited by
Cited by
Year
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T André, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, ...
New England Journal of Medicine 350 (23), 2343-2351, 2004
44342004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ...
Journal of Clinical Oncology 22 (2), 229-237, 2004
38912004
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ...
J clin oncol 27 (19), 3109-3116, 2009
27102009
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
25092017
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ...
Journal of clinical oncology 26 (3), 374-379, 2008
19502008
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
Journal of clinical oncology 36 (8), 773-779, 2018
18832018
Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ...
New England Journal of Medicine 383 (23), 2207-2218, 2020
18682020
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ...
The lancet oncology 14 (1), 29-37, 2013
13302013
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial
C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ...
Journal of Clinical Oncology 23 (15), 3509-3516, 2005
12552005
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
10742006
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib …
P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ...
Jama 315 (17), 1844-1853, 2016
10192016
Duration of adjuvant chemotherapy for stage III colon cancer
A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ...
New England Journal of Medicine 378 (13), 1177-1188, 2018
9052018
Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ...
Journal of Clinical Oncology 38 (1), 11, 2020
7802020
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
7802005
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009
7212009
Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status …
T André, A De Gramont, D Vernerey, B Chibaudel, F Bonnetain, ...
Journal of clinical oncology: official journal of the American Society of …, 2015
6942015
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
6382012
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
F Huguet, T André, P Hammel, P Artru, J Balosso, F Selle, ...
Journal of Clinical Oncology 25 (3), 326-331, 2007
6322007
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
J Clin Oncol 27 (19), 3117-3125, 2009
6012009
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients
C Louvet, T Andre, JM Tigaud, E Gamelin, JY Douillard, R Brunet, ...
Journal of Clinical Oncology 20 (23), 4543-4548, 2002
5892002
The system can't perform the operation now. Try again later.
Articles 1–20